株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

がん免疫療法の世界市場:2019年~2029年

Global Cancer Immunotherapy Market Forecast 2019-2029: Monoclonal Antibodies, Cytokines & Immunomodulators, Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy, Lung/Breast/Colorectal Cancer, Melanoma, Prostate/Head & Neck Cancer

発行 Visiongain Ltd 商品コード 602846
出版日 ページ情報 英文 194 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=143.96円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

Back to Top
がん免疫療法の世界市場:2019年~2029年 Global Cancer Immunotherapy Market Forecast 2019-2029: Monoclonal Antibodies, Cytokines & Immunomodulators, Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy, Lung/Breast/Colorectal Cancer, Melanoma, Prostate/Head & Neck Cancer
出版日: 2019年01月21日 ページ情報: 英文 194 Pages
概要

世界のがん免疫療法市場は、2018年に630億米ドルに達し、2019年~2024年のCAGR (複合年間成長率) で、11.4%の成長が予測されています。

当レポートでは、世界のがん免疫療法市場について調査分析し、市場概要、市場力学、市場予測、地域別予測、主要企業などについて、体系的な情報を提供しています。

第1章 レポート概要

第2章 がん免疫療法市場のイントロダクション

第3章 世界のがん免疫療法市場の予測

第4章 世界のがん免疫療法市場の予測:技術別

  • 概要
  • モノクローナル抗体
  • サイトカイン・免疫調節薬
  • その他

第5章 世界のがん免疫療法市場の予測:適応別

  • 概要
  • 肺がん
  • 乳がん
  • 大腸がん
  • メラノーマ
  • 前立腺がん
  • 頭頸部がん
  • その他

第6章 世界のがん免疫療法市場の予測:エンドユーザー別

  • 病院
  • がん研究センター
  • クリニック

第7章 地域別のがん免疫療法市場の予測

  • 市場予測
  • 北米
  • 南米
  • 欧州
  • アジア太平洋地域
  • その他

第8章 がん免疫療法市場:定性分析

  • ファイブフォース分析
  • 促進要因と抑制要因
  • 新興経済国の機会

第9章 がん免疫療法市場の主要企業

  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.
  • Medtronic plc.
  • Bristol-Myers Squibb
  • Novartis AG
  • Pfizer Inc.
  • Bayer AG
  • AstraZeneca Plc.
  • Eli Lilly and Company
  • Advaxis, Inc.

第10章 結論

図表

List of Tables

  • Table 2.1. Worldwide Estimated Incidence and Prevalence of all Cancer Types, (2012)
  • Table 3.1. Global Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%) 2018-2029
  • Table 4.1. Global Cancer Immunotherapy Market Forecast by Technology: ($m, AGR%, CAGR%), 2018-2029
  • Table 4.2. Types of Monoclonal Antibodies
  • Table 4.3. Therapeutic Monoclonal Antibodies Approved by FDA
  • Table 4.4. Global Monoclonal Antibodies for Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 4.5. Global Monoclonal Antibodies for Cancer Immunotherapy Market Forecast by Geography: ($m, AGR%, CAGR%) 2018-2029
  • Table 4.6. Global Cytokines & Immunomodulators for Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 4.7. Global Cytokines & Immunomodulators for Cancer Immunotherapy Market Forecast by Geography:($m, AGR%, CAGR%), 2018-2029
  • Table 4.8. Global Others Technologies for Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 4.9. Global Other Technologies for Cancer Immunotherapy Market Forecast by Geography: ($m, AGR%, CAGR%), 2018-2029
  • Table 5.1. Top Cancer Type in 2012
  • Table 5.2. Global Cancer Immunotherapy Market by Application: ($m, AGR%, CAGR%), 2018-2029
  • Table 5.3. Types of Monoclonal Antibodies
  • Table 5.4. Global Cancer Immunotherapy Market for Lung Cancer: ($m, AGR%, CAGR%), 2018-2029
  • Table 5.5. Global Cancer Immunotherapy Market for Lung Cancer by Geography: ($m, AGR%, CAGR%), 2018-2029
  • Table 5.6. Global Cancer Immunotherapy Market for Breast Cancer: ($m, AGR%, CAGR%), 2018-2029
  • Table 5.7. Global Cancer Immunotherapy Market for Breast Cancer by Geography: ($m, AGR%, CAGR%), 2018-2029
  • Table 5.8. Global Cancer Immunotherapy Market for Colorectal Cancer: ($m, AGR%, CAGR%), 2018-2029
  • Table 5.9. Global Cancer Immunotherapy Market for Colorectal Cancer by Geography: ($m, AGR%, CAGR%), 2018-2029
  • Table 5.10. Global Cancer Immunotherapy Market for Melanoma Cancer: ($m, AGR%, CAGR%), 2018-2029
  • Table 5.11. Global Cancer Immunotherapy Market for Melanoma Cancer by Geography: ($m, AGR%, CAGR%), 2018-2029
  • Table 5.12. Global Cancer Immunotherapy Market for Prostate Cancer: ($m, AGR%, CAGR%), 2018-2029
  • Table 5.13. Global Cancer Immunotherapy Market for Prostate Cancer by Geography: ($m, AGR%, CAGR%), 2018-2029
  • Table 5.14. Global Cancer Immunotherapy Market for Head & Neck Cancer: ($m, AGR%, CAGR%), 2018-2029
  • Table 5.15. Global Cancer Immunotherapy Market for Head & Neck Cancer by Geography: ($m, AGR%, CAGR%), 2018-2029
  • Table 5.16. Global Cancer Immunotherapy Market for Other Cancer types (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma): ($m, AGR%, CAGR%) 2018-2029
  • Table 5.17. Global Cancer Immunotherapy Market for Other Cancer Types (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma) by Geography: ($m, AGR%, CAGR%), 2018-2029
  • Table 6.1. Global Cancer Immunotherapy Market by End-User: ($m, AGR%, CAGR%), 2018-2029
  • Table 6.2. Global Cancer Immunotherapy Market Forecast for Hospital: ($m, AGR%, CAGR%), 2018-2029
  • Table 6.3. Global Cancer Immunotherapy Market Forecast for Hospital by Geography: ($m, AGR%, CAGR%), 2018-2029
  • Table 6.4. Funding Received by NCI ($m)
  • Table 6.5. Current Grants by Cancer Type as of August 2018
  • Table 6.6. Global Cancer Immunotherapy Market for Cancer Research Centres: ($m, AGR%, CAGR%), 2018-2029
  • Table 6.7. Global Cancer Immunotherapy Market Forecast for Cancer Research Centres by Geography: ($m, AGR%, CAGR%), 2018-2029
  • Table 6.8. Global Cancer Immunotherapy Market Forecast for Clinic: ($m, AGR%, CAGR%), 2018-2029
  • Table 6.9. Global Cancer Immunotherapy Market Forecast for Clinic by Geography: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.1. Global Cancer Immunotherapy Market Forecast by Geography: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.2. North America Cancer Immunotherapy Market Forecast by Country: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.3. North America Cancer Immunotherapy Market Forecast by Technology: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.4. North America Cancer Immunotherapy Market Forecast by Application: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.5. North America Cancer Immunotherapy Market Forecast by End User: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.6. US Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.7. Canada Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.8. Mexico Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.9. South America Cancer Immunotherapy Market Forecast by Country: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.10. South America Cancer Immunotherapy Market Forecast by Technology: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.11. South America Cancer Immunotherapy Market Forecast by Application: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.12. South America Cancer Immunotherapy Market Forecast by End User: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.13. Brazil Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.14. Argentina Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.15. Paraguay Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.16. Bolivia Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.17. Rest of South America Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.18. European Cancer Immunotherapy Market Forecast by Country: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.19. European Cancer Immunotherapy Market Forecast by Technology: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.20 European Cancer Immunotherapy Market Forecast by Application: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.21 European Cancer Immunotherapy Market Forecast by End-User: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.22. France Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.23. Germany Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.24. UK Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.25. Spain Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.26. Italy Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.27. Rest of European Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.28. Asia-Pacific Cancer Immunotherapy Market Forecast by Country: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.29. Asia-Pacific Cancer Immunotherapy Market Forecast by Technology: ($m, AGR%, CAGR%,), 2018-2029
  • Table 7.30. Asia-Pacific Cancer Immunotherapy Market Forecast by Application: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.31 Asia-Pacific Cancer Immunotherapy Market Forecast by End- User: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.32. China Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.33. Japan Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.34. India Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.35. Australia Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.36. Thailand Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.37. Rest of Asia-Pacific Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.38. Rest of World Cancer Immunotherapy Market Forecast by Country: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.39. Rest of World Cancer Immunotherapy Market Forecast by Technology: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.40 Rest of World Cancer Immunotherapy Market Forecast by Application: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.41 Rest of World Cancer Immunotherapy Market Forecast by End-User: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.42. Middle East Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.43. Africa Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 7.44. Other Countries Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
  • Table 9.1. F. Hoffmann-La Roche AG: Company Overview
  • Table 9.2. F. Hoffmann-La Roche AG: Product Portfolio
  • Table 9.3. F. Hoffmann-La Roche AG: Recent Developments
  • Table 9.4. Merck & Co., Inc.: Company Overview
  • Table 9.5. Merck & Co., Inc.: Product Portfolio
  • Table 9.6. Merck & Co., Inc.: Recent Development
  • Table 9.7. Medtronic plc.: Company Overview
  • Table 9.8. Medtronic plc.: Product Portfolio
  • Table 9.9. Medtronic plc.: Recent Developments
  • Table 9.10. Bristol-Myers Squibb: Company Overview
  • Table 9.11. Bristol-Myers Squibb: Product Portfolio
  • Table 9.12. Bristol-Myers Squibb: Recent Developments
  • Table 9.13 Novartis AG: Company Overview
  • Table 9.14. Novartis AG: Product Portfolio
  • Table 9.15. Novartis AG: Recent Developments
  • Table 9.16. Pfizer Inc.: Company Overview
  • Table 9.17. Pfizer Inc.: Product Portfolio
  • Table 9.18. Pfizer Inc.: Recent Development
  • Table 9.19. Bayer AG: Company Overview
  • Table 9.20. Bayer AG: Product Portfolio
  • Table 9.21. Bayer AG: Recent Development
  • Table 9.22. AstraZeneca Plc.: Company Overview
  • Table 9.23. AstraZeneca Plc.: Product Portfolio
  • Table 9.24. Eli Lilly and Company: Company Overview
  • Table 9.25. Eli Lilly and Company: Product Portfolio
  • Table 9.26. Eli Lilly and Company: Recent Development
  • Table 9.27. Advaxis, Inc.: Company Overview
  • Table 9.28. Advaxis, Inc.: Recent Developments
  • Table 10.1 Worldwide Estimated Prevalence of Cancer, 2012

List of Figures

  • Figure 1.1. Cancer immunotherapy Market Segmentation
  • Figure 2.1 Top winning Strategies of Market Players in Cancer Immunotherapy, 2014-2018
  • Figure 3.1 Cancer Immunotherapy Market by Technology: ($m), 2018-2029
  • Figure 3.2 Cancer Immunotherapy Market by Application: ($m), 2018-2029
  • Figure 3.3 Cancer Immunotherapy Market by End-User: ($m), 2018-2029
  • Figure 4.1 Cancer Immunotherapy Market by Technology: Market Share (%), 2018
  • Figure 4.2 Cancer Immunotherapy Market by Technology: Forecast ($m) 2018-2029
  • Figure 4.3 Global Monoclonal Antibodies for Cancer Immunotherapy Market Forecast by Geography: ($m) 2018-2029
  • Figure 4.4 Global Cytokines & Immunomodulators for Cancer Immunotherapy Market Forecast by Geography: ($m), 2018-2029
  • Figure 4.5 Global Other Technologies for Cancer Immunotherapy Market Forecast by Geography: ($m), 2018-2029
  • Figure 5.1. Global Cancer Immunotherapy Market by Application: ($m), 2018-2029
  • Figure 5.2. Global Cancer Immunotherapy Market by Application: Market Share (%), 2018
  • Figure 5.3. Global Cancer Immunotherapy Market for Lung Cancer Forecast by Geography: ($m), 2018-2029
  • Figure 5.4. Global Cancer Immunotherapy Market for Breast Cancer Forecast by Geography: ($m), 2018-2029
  • Figure 5.5. Global Cancer Immunotherapy Market for Colorectal Cancer Forecast, by Geography: ($m), 2018-2029
  • Figure 5.6. Global Cancer Immunotherapy Market for Melanoma Cancer Forecast by Geography: ($m), 2018-2029
  • Figure 5.7. Global Cancer Immunotherapy Market for Prostate Cancer Forecast, by Geography: ($m), 2018-2029
  • Figure 5.8. Global Cancer Immunotherapy Market for Head & Neck Cancer Forecast by Geography: ($m), 2018-2029
  • Figure 5.9. Global Cancer Immunotherapy Market for Other Cancer types (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma) Forecast by Geography: ($m), 2018-2029
  • Figure 6.0. Global Cancer Immunotherapy Market Forecast by End-User: ($m), 2018-2029
  • Figure 6.1 Global Cancer Immunotherapy Market by End-User: Market Share (%), 2018
  • Figure 6.2. Global Cancer Immunotherapy Market Forecast for Hospital by Geography: ($m), 2018-2029
  • Figure 6.3. Global Cancer Immunotherapy Market Forecast for Cancer Research Centres by Geography: ($m), 2018-2029
  • Figure 6.4 Global Cancer Immunotherapy Market Forecast for Clinic by Geography: ($m), 2018-2029
  • Figure 7.1. Global Cancer Immunotherapy Market Forecast by Geography: ($m), 2018-2029
  • Figure 7.2. Global Cancer Immunotherapy Market Forecast by Geography: Market Share (%), 2018
  • Figure 7.3. North America Cancer Immunotherapy Market by Country: Market Share (%), 2018
  • Figure 7.4. US Cancer Immunotherapy Market Forecast: ($m), 2018-2029
  • Figure 7.5. Estimation of diagnosis of Canadian Cancer Immunotherapy
  • Figure 7.6. Cancer Immunotherapy Market Forecast ($m), 2018-2029
  • Figure 7.7 Mexico Cancer Immunotherapy Market Forecast: ($m), 2018-2029
  • Figure 7.8 South America Cancer Immunotherapy Market Forecast by Country: ($m), 2018-2029
  • Figure 7.9 South America Cancer Immunotherapy Market by Country: Market Share (%), 2018
  • Figure 7.10. Brazil Cancer Immunotherapy Market Forecast: ($m), 2018-2029
  • Figure 7.11. Argentina Cancer Immunotherapy Market Forecast: ($m), 2018-2029
  • Figure 7.12. Paraguay Cancer Immunotherapy Market Forecast: ($m), 2018-2029
  • Figure 7.13. Bolivia Cancer Immunotherapy Market Forecast: ($m), 2018-2029
  • Figure 7.14. Rest of South America Cancer Immunotherapy Market Forecast: ($m), 2018-2029
  • Figure 7.15. Europe Cancer Immunotherapy Market Forecast by Country: ($m), 2018-2029
  • Figure 7.16. Europe Cancer Immunotherapy Market by Country: Market Share (%), 2018
  • Figure 7.17. France Cancer Immunotherapy Market Forecast: ($m), 2018-2029
  • Figure 7.18. Germany Cancer Immunotherapy Market Forecast: ($m), 2018-2029
  • Figure 7.19. UK Cancer Immunotherapy Market Forecast: ($m), 2018-2029
  • Figure 7.20. Spain Cancer Immunotherapy Market Forecast: ($m), 2018-2029
  • Figure 7.21. Italy Cancer Immunotherapy Market Forecast: ($m), 2018-2029
  • Figure 7.22. Rest of Europe Cancer Immunotherapy Market Forecast: ($m), 2018-2029
  • Figure 7.23. Asia-Pacific Cancer Immunotherapy Market Forecast by Country ($m) 2018-2029
  • Figure 7.24. Asia-Pacific Cancer Immunotherapy Market: Market Share (%), 2018
  • Figure 7.25. China Cancer Immunotherapy Market Forecast: ($m), 2018-2029
  • Figure 7.26. Japan Cancer Immunotherapy Market Forecast: ($m), 2018-2029
  • Figure 7.27. India Cancer Immunotherapy Market Forecast: ($m), 2018-2029
  • Figure 7.28. Australia Cancer Immunotherapy Market Forecast: ($m), 2018-2029
  • Figure 7.29. Thailand Cancer Immunotherapy Market Forecast: ($m,) 2018-2029
  • Figure 7.30. Rest of Asia-Pacific Cancer Immunotherapy Market Forecast: ($m), 2018-2029
  • Figure 7.31. RoW Cancer Immunotherapy Market Forecast by Country: ($m), 2018-2029
  • Figure 7.32. Rest of World Cancer Immunotherapy Market by Country: Market Share (%), 2018
  • Figure 7.33. Middle East Cancer Immunotherapy Market Forecast: ($m), 2018-2029
  • Figure 7.34. Africa Cancer Immunotherapy Market Forecast: ($m), 2018-2029
  • Figure 7.35. Other Countries Cancer Immunotherapy Market Forecast: ($m), 2018-2029
  • Figure 8.1 Porter's Five Forces Analysis of the Cancer Immunotherapy Market
  • Figure 9.1. F. Hoffmann-La Roche AG: Historical Revenue: ($m), 2013-2017
  • Figure 9.2. F. Hoffmann-La Roche AG: Product Segments Share (%), 2017
  • Figure 9.3. F. Hoffmann-La Roche AG: Geographical Presence Share (%), 2017
  • Figure 9.4. Merck & Co., Inc.: Historical Revenue ($m), 2013-2017
  • Figure 9.5. Merck & Co., Inc.: Product Segments Share (%), 2017
  • Figure 9.6. Merck & Co., Inc.: Geographical Presence Share (%), 2017
  • Figure 9.7. Medtronic plc.: Historical Revenue ($m), 2014-2018
  • Figure 9.8. Medtronic plc.: Product Segments Share (%), 2018
  • Figure 9.9. Medtronic plc.: Geographical Presence Share (%), 2018
  • Figure 9.10. Bristol-Myers Squibb: Historical Revenue ($m), 2013-2017
  • Figure 9.11. Bristol-Myers Squibb: Product Segments Share (%), 2017
  • Figure 9.12. Bristol-Myers Squibb: Geographical Presence Share (%), 2017
  • Figure 9.13. Novartis AG: Historical Revenue ($m), 2013-2017
  • Figure 9.14. Novartis AG: Product Segments Share (%), 2017
  • Figure 9.15. Novartis AG: Geographical Presence Share (%), 2017
  • Figure 9.16. Pfizer Inc., Historical Revenue, ($m), 2013-2017
  • Figure 9.17. Pfizer Inc.: Product Segments Share (%), 2017
  • Figure 9.18. Pfizer Inc.: Geographical Presence Share (%), 2017
  • Figure 9.19. Bayer AG: Historical Revenue, ($m), 2013-2017
  • Figure 9.20. Bayer AG: Product Segments Share (%), 2017
  • Figure 9.21. Bayer AG: Geography Presence Share (%), 2018
  • Figure 9.22. AstraZeneca Plc.: Historical Revenue, ($m), 2013-2017
  • Figure 9.23. AstraZeneca Plc.: Product Segments Share (%), 2017
  • Figure 9.24. AstraZeneca Plc.: Geographical Presence Share (%), 2017
  • Figure 9.25. Eli Lilly and Company: Historical Revenue ($m), 2013-2018
  • Figure 9.26. Eli Lilly and Company: Product Segments Share (%), 2017
  • Figure 9.27. Eli Lilly and Company: Geographical Presence Share (%), 2017
  • Figure 9.28. Advaxis, Inc.: Historical Revenue ($m), 2014-2017
  • Figure 9.29. Advaxis, Inc.: Product Segments Share (%), 2017
  • Figure 10.1 World Cancer Immunotherapy by Technology: ($m), 2018-2029
  • Figure 10.2 World Cancer Immunotherapy by Application: ($m), 2018-2029
  • Figure 10.3 World Cancer Immunotherapy by End-User: ($m), 2018-2029
  • Figure 10.4 World Cancer Immunotherapy by Geography: ($m), 2018-2029
目次
Product Code: PHA0351

The world cancer immunotherapy market is expected to grow at a CAGR of 11.4% in the second half of the forecast period. The market reached $63bn in 2018, dominated by the monoclonal antibody segment which held 66% share of the market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 194-page report you will receive 110 tables and 93 figures- all unavailable elsewhere.

The 194-page report provides clear detailed insight into the global cancer-treating drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global cancer immunotherapy market forecasts from 2019-2029
  • This report also breaks down the revenue forecast for the global cancer immunotherapy market by Technology:
    • Monoclonal Antibodies
    • Cytokines & immunomodulators
    • Others (Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy)

Each submarket is further broken down by region: North America, South America, Europe, Asia-Pacific and ROW.

  • This report also breaks down the revenue forecast for the global cancer immunotherapy market by Application:
    • Lung Cancer
    • Breast Cancer
    • Colorectal cancer
    • Melanoma Cancer
    • Prostate Cancer
    • Head & Neck Cancer,
    • Others (Renal Cell Carcinoma, Cervical, Gastric, Lymphoma)

Each submarket is further broken down by region: North America, South America, Europe, Asia-Pacific and ROW.

  • This report also breaks down the revenue forecast for the world cancer immunotherapy market by End-User:
    • Hospitals
    • Cancer Research Centers
    • Clinics

Each submarket is further broken down by region: North America, South America, Europe, Asia-Pacific and ROW.

  • This report provides individual revenue forecasts to 2029 for these regional and national markets:
    • North America: US, Canada, Mexico
    • South America: Brazil, Argentina, Paraguay, Bolivia, Rest of South America
    • Europe: The UK, Germany, France, Spain, Italy, Rest of Europe
    • Asia-Pacific: China, Japan, India, Australia, Thailand, Rest of Asia-Pacific
    • Rest of World: Middle East, Africa, Other Countries

Each regional market is further broken down by technology, application and end-user.

  • This report discusses trends in the industry and assesses drivers and restraints, as well as opportunities and threats. It also includes porters' five force analysis; threat of new entrants, power of suppliers, power of buyers, rivalry among competitors and threat of substituents.
  • Our study discusses the selected leading companies that are the major players in the cancer immunotherapy market:
    • Adaxic Inc
    • AstraZeneca
    • Bayer
    • Bristol-Myers Squibb (BMS)
    • Eli Lilly and Co.
    • Medtronic Plc
    • Merck & Co., Inc. (Merck)
    • Novartis
    • Pfizer
    • Roche

image1

The report provides overviews of the companies, financial information, product portfolio, pipeline products and recent developments.

Visiongain's study is intended for anyone requiring commercial analyses for the global cancer Immunotherapy market. You find data, trends and predictions.

Buy our report today Global Cancer Immunotherapy Market Forecast 2019-2029: Monoclonal Antibodies, Cytokines & Immunomodulators, Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy, Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, Hospitals, Cancer Research Centers, Clinics.

Table of Contents

1. Report Overview

  • 1.1 Global Cancer Immunotherapy Market Overview
  • 1.2 Market Definition
  • 1.3 Research Methodology
    • 1.3.1 Primary Research
    • 1.3.2 Secondary Research
    • 1.3.3 Market Evaluation & Forecasting Methodology
  • 1.4 Global Cancer Immunotherapy Market Segmentation
  • 1.5 Overview of Findings
  • 1.6 Why You Should Read This Report
  • 1.7 How this report delivers?
  • 1.8 Key Questions Answered by This Analytical Report
  • 1.9 Frequently Asked Questions (FAQ)
  • 1.10 Who is This Report For?
  • 1.11 Associated Visiongain Reports
  • 1.12 About Visiongain

2. Introduction to Cancer Immunotherapy Market

3. Global Cancer Immunotherapy Market Forecast 2019 - 2029

4. Global Cancer Immunotherapy Market by Technology: Market Forecast 2019 - 2029

  • 4.1 Overview
  • 4.2 Monoclonal antibodies
  • 4.3 Cytokines & Immunomodulators
  • 4.4 Others (Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy)

5. Global Cancer Immunotherapy Market by Application: Market Forecast 2019 - 2029

  • 5.1 Overview
  • 5.2 Lung Cancer
  • 5.3 Breast Cancer
  • 5.4 Colorectal Cancer
  • 5.5 Melanoma
  • 5.6 Prostate Cancer
  • 5.7 Head & Neck Cancer
  • 5.8 Other Cancer types (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma)

6. Global Cancer Immunotherapy Market by End-User: Market Forecast 2019 - 2029

  • 6.1 Hospitals
  • 6.2 Cancer Research Centres
  • 6.3 Clinics

7. Regional Cancer Immunotherapy Market Forecasts 2019-2029

  • 7.1 Regional Cancer Immunotherapy Market Forecast 2018-2029
  • 7.2 North American Cancer Immunotherapy Market Forecast 2018-2029
    • 7.2.1 USA Cancer Immunotherapy Market Forecast 2018-2029
    • 7.2.2 Canada Cancer Immunotherapy Market Forecast 2018-2029
    • 7.2.3 Mexico Cancer Immunotherapy Market Forecast 2018-2029
  • 7.3 South American Cancer Immunotherapy Market Forecast 2018-2029
    • 7.3.1 Brazil Cancer Immunotherapy Market Forecast 2018-2029
    • 7.3. 2 Argentina Cancer Immunotherapy Market Forecast 2018-2029
    • 7.3.3 Paraguay Cancer Immunotherapy Market Forecast 2018-2029
    • 7.3.4 Bolivia Cancer Immunotherapy Market Forecast 2018-2029
    • 7.3.5 Rest of South America Cancer Immunotherapy Market Forecast 2018-2029
  • 7.4 European Cancer Immunotherapy Market Forecast 2018-2029
    • 7.4.1 France Cancer Immunotherapy Market Forecast 2018-2029
    • 7.4.2 Germany Cancer Immunotherapy Market Forecast 2018-2029
    • 7.4.3 UK Cancer Immunotherapy Market Forecast 2018-2029
    • 7.4.4 Spain Cancer Immunotherapy Market Forecast 2018-2029
    • 7.4.5 Italy Cancer Immunotherapy Market Forecast 2018-2029
    • 7.4.6 Rest of Europe Cancer Immunotherapy Market Forecast 2018-2029
  • 7.5 Asia-Pacific Cancer Immunotherapy Market Forecast 2018-2029
    • 7.5.1 China Cancer Immunotherapy Market Forecast 2018-2029
    • 7.5.2 Japan Cancer Immunotherapy Market Forecast 2018-2029
    • 7.5.3 India Cancer Immunotherapy Market Forecast 2018-2029
    • 7.5.4 Australia Cancer Immunotherapy Market Forecast 2018-2029
    • 7.5.5 Thailand Cancer Immunotherapy Market Forecast 2018-2029
    • 7.5.6 Rest of Asia-Pacific Cancer Immunotherapy Market Forecast 2018-2029
  • 7.6 Rest of World Cancer Immunotherapy Market Forecast 2018-2029
    • 7.6.1 Middle East Cancer Immunotherapy Market Forecast 2018-2029
    • 7.6.2 Africa Cancer Immunotherapy Market Forecast 2018-2029
    • 7.6.3 Other Countries Cancer Immunotherapy Market Forecast 2018-2029

8. Cancer Immunotherapy Market: Qualitative Analysis

  • 8.1 Porter's Five Forces Analysis of the Cancer Immunotherapy Market
  • 8.2 Bargaining Power of Buyers (Low)
  • 8.3 Bargaining Power of Suppliers (High)
  • 8.4 Threat of New Entrants (Low)
  • 8.5 Threat of Substitute Products (High)
  • 8.6 Intensity of Competitive Rivalry (High)
  • 8.7 Drivers & Restrains
  • 8.8 Increasing Prevalence of Cancer
  • 8.9 Increasing Research in Cancer Immunotherapy
  • 8.10 High Cost of Cancer Immunotherapy
  • 8.11 Increasing Funding for the Cancer Research by Governmental Organisations
  • 8.12 Increasing Investment from Government, Public and Private Sector
  • 8.13 Increased Focus Towards Advanced Treatment Protocols
  • 8.14 Significant Unmet Need in Cancer Diagnosis
  • 8.15 Increased Awareness to Reduce Healthcare Costs
  • 8.16 Opportunities in Emerging Economies

9. Leading Companies in Cancer Immunotherapy Market

  • 9.1 F. Hoffmann-La Roche AG
    • 9.1.1 F. Hoffmann-La Roche AG: Company Overview
    • 9.1.2 F. Hoffmann-La Roche AG: Business Performance
    • 9.1.3 F. Hoffmann-La Roche AG: Product Portfolio
    • 9.1.4 F. Hoffmann-La Roche AG: Recent Developments
  • 9.2 Merck & Co., Inc.
    • 9.2.1 Merck & Co., Inc.: Company Overview
    • 9.2.2 Merck & Co., Inc.: Business Performance
    • 9.2.3 Merck & Co., Inc.: Product Portfolio
    • 9.2.4 Merck & Co., Inc.: Recent Development
  • 9.3 Medtronic plc.
    • 9.3.1 Medtronic plc.: Company Overview
    • 9.3.2 Medtronic plc.: Business Performance
    • 9.3.3 Medtronic plc.: Product Portfolio
    • 9.3.4 Medtronic plc.: Recent Developments
  • 9.4 Bristol-Myers Squibb
    • 9.4.1 Bristol-Myers Squibb: Company Overview
    • 9.4.2 Bristol-Myers Squibb: Business Performance
    • 9.4.3 Bristol-Myers Squibb: Product Portfolio
    • 9.4.4 Bristol-Myers Squibb: Recent Developments
  • 9.5 Novartis AG
    • 9.5.1 Novartis AG: Company Overview
    • 9.5.2 Novartis AG: Business Performance
    • 9.5.3 Novartis AG: Product Portfolio
    • 9.5.4 Novartis AG: Recent Developments
  • 9.6 Pfizer Inc.
    • 9.6.1 Pfizer Inc.: Company Overview
    • 9.6.2 Pfizer Inc.: Business Performance
    • 9.6.3 Pfizer Inc.: Product Portfolio
    • 9.6.4 Pfizer Inc.: Recent Developments
  • 9.7 Bayer AG
    • 9.7.1 Bayer AG: Company Overview
    • 9.7.2 Bayer AG: Business Performance
    • 9.7.3 Bayer AG: Product Portfolio
    • 9.7.4 Bayer AG: Recent Development
  • 9.8 AstraZeneca Plc.
    • 9.8.1 AstraZeneca Plc.: Company Overview
    • 9.8.2 AstraZeneca Plc.: Business Performance
    • 9.8.3 AstraZeneca Plc.: Product Portfolio
  • 9.9 Eli Lilly and Company
    • 9.9.1 Eli Lilly and Company: Company Overview
    • 9.9.2 Eli Lilly and Company: Business Performance
    • 9.9.3 Eli Lilly and Company: Product Portfolio
    • 9.9.4 Eli Lilly and Company: Recent Development
  • 9.10 Advaxis, Inc.
    • 9.10.1 Advaxis, Inc.: Recent Development
    • 9.10.2 Advaxis, Inc.: Business Performance
    • 9.10.3 Advaxis, Inc.: Recent Development

10. Conclusions

  • 10.1 Current Leading Segments
  • 10.2 Leading Regional Markets
  • 10.3 Emerging Markets
  • 10.4 The Future of the Market?

Associated Visiongain Reports

  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

Companies Listed

  • Abbott Laboratories
  • Adaptimmune Therapeutics plc
  • Admune Therapeutics
  • Aduro Biotech
  • Advaxis Inc.
  • Alcon
  • Amgen
  • Astrazeneca UK
  • Bayer AG
  • Baylis Medical
  • BioInvent International
  • BioNTech AG.
  • Biothera
  • Bristol-Mayers Squibb
  • cCAM Biotherapeutics Ltd.
  • Celgene
  • Dendreon
  • Dragonfly
  • Eli Lilly
  • Endocyte, Inc
  • F. Hoffmann-La Roche Ltd
  • Flexus Biosciences, Inc.
  • Genentech (Roche)
  • Genomic Health, Inc.
  • GlaxoSmithKline
  • Incyte
  • IOmet Pharma Ltd
  • Janssen Biotech, Inc.
  • Medtronic
  • Merck & Co., Inc.
  • Merck Sharp & Dohme Limited
  • Moderna Therapeutics
  • NextCure
  • Novartis AG
  • Novartis Pharms Corp
  • Palobiofarma
  • Pfizer, Inc.
  • Qiagen N.V.
  • Regeneron Pharmaceuticals Inc
  • Sandoz
  • Sellas
  • Teva Pharmaceuticals Limited
  • Valeant Pharmaceuticals international

List of Organizations Mentioned in the Report

  • American Association of Cancer Research
  • American Cancer Society
  • American Institute for Cancer Research
  • Association of American Cancer Institutes
  • Canadian Cancer society
  • Cancer Research Institute
  • CDC
  • China Center for Food and Drug International Exchange (CCFDIE)
  • Chinese American Hematologist and Oncologist Network (CAHON)
  • European Commission
  • FDA
  • Fred Hutchinson Cancer Research Center
  • National Cancer Institute
  • Parker Institute for Cancer Immunotherapy
  • Seattle Cancer Care Alliance
  • Seattle Children's Hospital
  • The German Cancer Research Center
  • University of Chicago
  • University of Washington Medical Center
  • WHO
Back to Top